Sema4 Holdings ($SMFR) Investor Settlement

Sema4 Holdings has reached a tentative settlement to resolve investor claims that it overstated the capabilities of Centrellis and the business benefits expected from the GeneDx transaction.

Outline:

On January 18, 2022, Sema4 announced its GeneDx deal and said the combination would strengthen Centrellis and help drive major revenue growth. On August 15, 2022, Sema4 changed strategy, cut about 250 employees, and announced leadership changes, and $SMFR fell 33.3% the next day. The case has now moved to a tentative settlement.

Timeline:

• January 18, 2022: Sema4 announced an agreement to acquire GeneDx for $623 million and said the deal would help deliver $350 million in 2022 revenue.

• March 14, 2022: Sema4 reported results and again promoted Centrellis as a sophisticated platform that would be strengthened by the GeneDx deal.

• May 2, 2022: Sema4 closed the GeneDx acquisition and a $200 million private placement.

• June 16, 2022: Sema4 described Centrellis as a data engine that could deliver improved and personalized health insights.

• August 15, 2022: Sema4 announced major changes to its R&D strategy, leadership, and workforce, including about 250 job cuts.

• August 16, 2022: $SMFR fell 33.3% to close at $1.60 per share.

• November 14, 2022: Sema4 said it would exit reproductive health testing and somatic oncology testing and cut about 500 more employees.

• January 9, 2023: Sema4 projected 2022 revenue of $170 million to $173 million and said it expected profitability in 2025.

• March 2026: Sema4 agrees to settle the lawsuit.

Background:

Sema4 was a health diagnostics company that wanted to expand beyond testing and build a larger data and analytics business around its Centrellis platform. The company said Centrellis could organize and analyze large volumes of clinical and genomic data to generate personalized health insights for patients, providers, health systems, and biopharma companies.

In January 2022, Sema4 announced a deal to acquire GeneDx and said the transaction would strengthen Centrellis with hundreds of thousands of clinical exomes and millions of annotated phenotypes. The company also said the combined business was projected to generate $350 million in 2022 revenue and would be better positioned to commercialize its data strategy.

Investors say that the picture was overstated. According to the case, Centrellis could not meaningfully use the health-system data Sema4 had gathered, lacked a clear product strategy, faced patient-consent and compliance hurdles, and remained years away from becoming the kind of commercial platform the company had described.

Even so, Sema4 continued promoting Centrellis through spring and summer 2022. Then, on August 15, 2022, the company announced a major reset, including a new R&D approach, leadership changes, and about 250 layoffs, while saying it needed to focus on building scalable products. The stock fell 33.3% the next day.

Later updates added to the pressure. In November 2022, Sema4 said it would shut down key testing businesses and cut about 500 more employees, and in January 2023 it projected revenue far below the level it had highlighted when announcing the GeneDx deal. The matter has now moved to a proposed settlement, although the materials provided do not state the amount or the next key dates.

What Can Investors Expect Now?

Sema4 Holdings has reached a tentative settlement to resolve investor claims that it overstated the capabilities of Centrellis and the business benefits expected from the GeneDx transaction.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.